Bioavailability Study of Anti Nausea Medication With and Without Food

NCT ID: NCT00905190

Last Updated: 2017-02-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 22 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-02-28
• Study Completion Date: 2009-03-31

Brief Summary

This study is to assess the effect of food on a single dose of EUR-1025 when taken with a meal and taken on an empty stomach.

Detailed Description

The objective of this study is to assess the effect of food on the pharmacokinetics of a single 24 mg dose of EUR-1025 administered as a novel modified-release capsule formulation under fed and fasting conditions.

Conditions

Nausea

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Fed

A single oral dose of ondansetron (1 x 24 mg) will be administered with approximately 240 ml of water in the morning. The ondansetron dose will be administered after a 10-hour overnight fast and thirty minutes after consuming a high-fat, high-caloric breakfast

Group Type: EXPERIMENTAL

Ondansetron

Intervention Type: DRUG

24 mg one time

Fasting

A single oral dose of ondansetron (1 x 24 mg) will be administered with approximately 240 ml of water in the morning after a 10-hour overnight fast.

Group Type: EXPERIMENTAL

Ondansetron

Intervention Type: DRUG

24 mg one time

Interventions

Ondansetron

24 mg one time

Intervention Type: DRUG

Other Intervention Names

EUR-1025

Eligibility Criteria

Inclusion Criteria

• Male and female volunteers,
• Non- or ex-smokers,
• Of at least 21 years of age but not older than 55 years with a body mass index targeted to be at least 18.5 and less than 30 kg/m2,
• Healthy, normal lab values,
• Negative HIV, Hepatitis B & C and a negative ethyl alcohol and drug screen,
• Normal 12 lead ECG, negative human chorionic gonadotropin (hCG) for females.

Exclusion Criteria

• No known hypersensitivity to Ondansetron or any related products,
• Presence of significant gastrointestinal, liver or kidney disease,or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects,
• History of significant gastrointestinal, liver or kidney disease,
• Presence of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease,
• Suicidal tendency,
• History of or disposition to seizures, state of confusion, clinically relevant psychiatric disease,
• Presence of significant heart disease or disorder discovered on screening ECG,
• Females who are found to have a positive serum pregnancy test at screening or are nursing,
• Females of childbearing potential who refuse to use an acceptable contraceptive regimen from the screening visit and throughout the study,
• Maintenance therapy with any drug,
• Significant history of drug dependency or alcohol abuse (> 2 units of alcohol per day, intake of excessive alcohol, acute or chronic),
• Any clinically significant illness in the previous 28 days before day 1 of the study,
• Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin,fluconazole, ketoconazole,diltiazem and HIV antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin and rifampin), in the previous 28 days before day 1 of this study,
• Volunteers who took an Investigational Product (in another clinical trial) or donated 50 ml or more of blood in the previous 28 days before day 1 of this study,
• Poor motivation, intellectual problems likely to limit the validity of consent to participate in the study or limit the ability to comply with the protocol requirements or inability to cooperate adequately,
• Inability to understand and to observe the instructions of the physician,
• Donation of 500 ml or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies) in the previous 56 days before day 1 of this study,
• Positive urine screening of drugs or abuse,
• Any history of tuberculosis and/or prophylaxis for tuberculosis,
• Positive results to HIV, HBsAg, or anti-HCV tests,
• No subjects will be allowed to enroll in this study more than once.

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Forest Laboratories

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Eric Sicard, M.D.

Role: PRINCIPAL_INVESTIGATOR

Algorithme Pharma Inc

Locations

Algorithme Pharma INc.

Mount Royal, Quebec, Canada

Countries

Canada

Other Identifiers

ODO-P8-689

Identifier Type: -

Identifier Source: org_study_id